Is BTTX or UPHL more profitable?

Company Net Margins Return on Equity Return on Assets Better Therapeutics N/A N/A N/A UpHealth N/A N/A N/A

Is GNCA or UPHL more profitable?

UpHealth's return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182.88% -62.76% UpHealth N/A N/A N/A

Is UPHL or PXMD more profitable?

UpHealth's return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets UpHealth N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Is ARDS or UPHL more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A UpHealth N/A N/A N/A

Which has better valuation & earnings, UPHL or GNCAQ?

Genocea Biosciences has lower revenue, but higher earnings than UpHealth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio UpHealth $130M 0.00 -$56.42M $1.98 0.00 Genocea Biosciences N/A N/A N/A N/A N/A

Is UPHL or GNCAQ more profitable?

Company Net Margins Return on Equity Return on Assets UpHealth N/A N/A N/A Genocea Biosciences N/A N/A N/A

UpHealth (UPHL) Competitors

$0.0001 0.00 (0.00%)

As of 10/5/2026 09:31 AM Eastern

Compare

UPHL vs. BTTX, GNCA, PXMD, ARDS, and GNCAQ

Should you buy UpHealth stock or one of its competitors? UpHealth's main competitors and comparable companies include Better Therapeutics (BTTX), Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does UpHealth compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Better Therapeutics has higher earnings, but lower revenue than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Better Therapeutics	N/A	N/A	-$39.76M	-$0.39	N/A
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 34.2% of UpHealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Better Therapeutics	N/A	N/A	N/A
UpHealth	N/A	N/A	N/A

Better Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company	Overall Sentiment
Better Therapeutics	Neutral
UpHealth	Neutral

Summary

UpHealth beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

How does UpHealth compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
UpHealth	Neutral

Genocea Biosciences has higher earnings, but lower revenue than UpHealth. Genocea Biosciences is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, UpHealth has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 34.2% of UpHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

UpHealth's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
UpHealth	N/A	N/A	N/A

Summary

UpHealth beats Genocea Biosciences on 7 of the 9 factors compared between the two stocks.

How does UpHealth compare to PaxMedica?

UpHealth (NYSE:UPHL) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

UpHealth's return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UpHealth	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

PaxMedica has lower revenue, but higher earnings than UpHealth. PaxMedica is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

In the previous week, UpHealth's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
UpHealth	Neutral
PaxMedica	Neutral

UpHealth has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

56.1% of UpHealth shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 34.2% of UpHealth shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

UpHealth beats PaxMedica on 8 of the 9 factors compared between the two stocks.

How does UpHealth compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
UpHealth	N/A	N/A	N/A

Aridis Pharmaceuticals has higher earnings, but lower revenue than UpHealth. UpHealth is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
UpHealth	Neutral

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 34.2% of UpHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aridis Pharmaceuticals has a beta of 47.61, meaning that its stock price is 4,661% more volatile than the broader market. Comparatively, UpHealth has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Summary

UpHealth beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does UpHealth compare to Genocea Biosciences?

UpHealth (NYSE:UPHL) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

56.1% of UpHealth shares are held by institutional investors. 34.2% of UpHealth shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

UpHealth has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
UpHealth	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

Genocea Biosciences has lower revenue, but higher earnings than UpHealth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

In the previous week, UpHealth's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
UpHealth	Neutral
Genocea Biosciences	Neutral

Summary

UpHealth beats Genocea Biosciences on 4 of the 5 factors compared between the two stocks.

Get UpHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

UPHL vs. The Competition

Export

Metric	UpHealth	Health services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2K	$3.14M	$7.15B	$22.78B
Dividend Yield	N/A	N/A	2.53%	3.72%
P/E Ratio	0.00	N/A	274.34	27.90
Price / Sales	0.00	0.00	619.11	20.32
Price / Cash	N/A	N/A	27.22	19.11
Price / Book	0.00	0.00	11.23	4.70
Net Income	-$56.42M	-$56.42M	$3.49B	$1.07B
7 Day Performance	N/A	N/A	-1.31%	0.47%
1 Month Performance	N/A	N/A	-5.97%	-5.36%
1 Year Performance	N/A	N/A	7.26%	5.39%

UpHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPHL UpHealth	N/A	$0.00 flat	N/A	-50.0%	$2K	$130M	N/A	374
BTTX Better Therapeutics	N/A	N/A	N/A	N/A	$4K	N/A	N/A	40	Gap Down
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	6	Gap Up
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	-50.0%	$5K	N/A	0.00	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:UPHL) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

UpHealth (UPHL) Competitors

UPHL vs. BTTX, GNCA, PXMD, ARDS, and GNCAQ

How does UpHealth compare to Better Therapeutics?

Summary

How does UpHealth compare to Genocea Biosciences?

Summary

How does UpHealth compare to PaxMedica?

Summary

How does UpHealth compare to Aridis Pharmaceuticals?

Summary

How does UpHealth compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

UPHL vs. The Competition

UpHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

UpHealth (UPHL) Competitors

UPHL vs. BTTX, GNCA, PXMD, ARDS, and GNCAQ

How does UpHealth compare to Better Therapeutics?

Which has preferable earnings and valuation, BTTX or UPHL?

Do insiders and institutionals have more ownership in BTTX or UPHL?

Is BTTX or UPHL more profitable?

Which has more volatility & risk, BTTX or UPHL?

Does the media refer more to BTTX or UPHL?

Summary

How does UpHealth compare to Genocea Biosciences?

Does the media refer more to GNCA or UPHL?

Which has stronger earnings and valuation, GNCA or UPHL?

Which has more volatility and risk, GNCA or UPHL?

Do insiders & institutionals hold more shares of GNCA or UPHL?

Is GNCA or UPHL more profitable?

Summary

How does UpHealth compare to PaxMedica?

Is UPHL or PXMD more profitable?

Which has better valuation and earnings, UPHL or PXMD?

Does the media favor UPHL or PXMD?

Which has more risk & volatility, UPHL or PXMD?

Do insiders & institutionals have more ownership in UPHL or PXMD?

Summary

How does UpHealth compare to Aridis Pharmaceuticals?

Is ARDS or UPHL more profitable?

Which has stronger earnings & valuation, ARDS or UPHL?

Does the media prefer ARDS or UPHL?

Do insiders & institutionals hold more shares of ARDS or UPHL?

Which has more risk and volatility, ARDS or UPHL?

Summary

How does UpHealth compare to Genocea Biosciences?

Do insiders & institutionals hold more shares of UPHL or GNCAQ?

Which has more volatility and risk, UPHL or GNCAQ?

Is UPHL or GNCAQ more profitable?

Which has better valuation & earnings, UPHL or GNCAQ?

Does the media refer more to UPHL or GNCAQ?

Summary

New MarketBeat Followers Over Time

UPHL vs. The Competition

UpHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools